IntelliPharmaCeutics Announces FDA Acceptance For Filing Of NDA For Rexista (Oxycodone Hydrochloride Extended Release), An Abuse Deterrent Opioid Analgesic For The Treatment Of Moderate To Severe Pain Post author:Sam Post published:February 2, 2017 Post category:BioPharma Life Sciences Jobs … Source: BioSpace You Might Also Like Lilly's Cyramza Fails to Improve Overall Survival in Phase III Gastric Cancer Study December 10, 2017 Nemaura Pharma Appoints As Director Of Strategic Alliances April 6, 2017 DaVita Clinical Research Launches Alliance Site Network For Early Stage CKD Trials June 14, 2017
Lilly's Cyramza Fails to Improve Overall Survival in Phase III Gastric Cancer Study December 10, 2017